1. P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T-CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA. (23rd June 2022) Authors: Dalovisio, A.; Bahlis, N.; Raje, N.; Costello, C.; Dholaria, B.; Solh, M.; Levy, M.; Tomasson, M.; Dube, H.; Damore, M.; Jiang, S.; Basu, C.; Skoura, A.; Chan, E.; Trudel, S.; Jakubowiak, A.; Chu, M.; Gasparetto, C.; Sebag, M.; Lesokhin, A. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 788 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗